MEDAVIE BLUE CROSS™

PRIOR AUTHORIZATION REQUEST

PROCEDURES FOR PRIOR AUTHORIZATION

Completed forms can be faxed in confidence to 1-514-286-8480 for residents of Quebec and 1-844-661-2640 for residents of all other provinces

Upon receipt, this request will be confidentially reviewed according to payment criteria developed by Medavie Blue Cross in consultation with independent health care consultants. In some cases, additional clinical or diagnostic information may be required to process your claim.

For Quebec residents, the criteria for prior authorization are adjusted to meet the requirements of the Régie de l'assurance maladie du Québec (RAMQ).

- Prior Authorization is a pre-approval process to determine if certain products will be reimbursed under a member's benefit plan.
- Please complete entire form. Incomplete forms cannot be processed.
- **For certain medications, approval for reimbursement may be conditional on confirmation of enrollment in the patient support program.**
- Prior Authorization may be limited to a specified period or quantity of medication.
  Some Medavie Blue Cross plans may require you to purchase a drug requiring prior authorization from a preferred pharmacy*. If your prior authorization request is approved, a case manager may contact you, your physician, or Patient Assistance Program to provide information about the program and to arrange to have your prescription transferred to the preferred pharmacy.
  **Not applicable in Quebec*.
- In cases where a request for Prior Authorization is declined, Medavie Blue Cross is denying payment for a product and is not challenging the medical opinion of the physician nor rendering a medical opinion.
- Any costs associated with the completion of this form or obtainment of additional medical information are the responsibility of the member.
- Renewal of the Prior Authorization will be considered by Medavie Blue Cross upon request from the patient/member. The renewal request should include information from the physician supporting continued use of the medication.
- Prior Authorization coverage is contingent on your continued status as a Medavie Blue Cross cardholder or beneficiary.
- If this is a request under the *Mesure du patient d'exception* for a Quebec resident, please include a completed *Patient d'exception* form that can be found here: www.medaviebc.ca/en/resources, in addition to this document.
- If you would like more information about our Patient First Network, including how your Patient Support Program can become integrated with our new enhanced Prior Authorization processes, please send an e-mail to: patientfirstnetwork@medavie.bluecross.ca.

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480

MEDAVIE BLUE CROSS™

PRIOR AUTHORIZATION REQUEST

1 PHARMACY INFORMATION

This section is to be completed by the Professional coordinating the request on behalf of the member (PSP, Cancer Care Navigator or Pharmacy)

Decision communication preference: ☐ Fax, Number: _____ ☐ Telephone, Number: _____

Name of Program/Pharmacy: _____

Contact Name: _____ Contact E-mail: _____

2 PATIENT INFORMATION

Part A

Patient Name: _____ Date of Birth: _____ (mm/dd/yyyy)

E-mail address of patient (or of legal guardian if patient is underage): _____

Address: _____ Suite: _____ City: _____

Province: _____ Postal Code: _____ Telephone Number: _____

Policy Number: _____ ID Number: _____

Do you have valid Medicare coverage in your current province of residence? ☐ Yes ☐ No

Have you already purchased this prescription? ☐ Yes ☐ No

Please attach your paid-in-full receipt with this request form. If you have already submitted your receipt to Medavie Blue Cross, please indicate the date of the oldest receipt. Date: _____ (mm/dd/yyyy)

Part B – Coordination of Benefits

Do you or any dependant have coverage for this drug under any other plan or program? ☐ Yes ☐ No **If Yes, complete the following:**

Policy Number: _____ Carrier: _____

(If applicable, please attach Explanation of Benefits from prior carrier with complete form)

If the patient is a dependent, provide the birth day and month of the cardholder for the other carrier: _____ (mm/dd)

Public-Funded Program – Have you applied for coverage through a public-funded program? ☐ Yes ☐ No

If No, please indicate why: _____

Part C – Authorization

I understand that the personal information I have provided herein is collected and used by Medavie Blue Cross to administer the terms of my policy or the group policy of which I am an eligible member, recommend suitable products and services that I am eligible for as a member of a policy, and other applicable purposes, as described in the Medavie Blue Cross Privacy Statement at **www.medaviebc.ca.**

Depending on the type of coverage I carry, limited personal information such as claim, health and/or financial related data may be collected from and/or released to following third parties as required for the purposes of administering and managing the benefits outlined in the policy of which I am an eligible member. These third parties may include healthcare providers, other insurance companies, regulatory authorities and investigative bodies, services providers, and/or the cardholder of any contract under which I am a participant.

Where allowed by law, my information may be shared with Medavie Blue Cross employees or service providers in jurisdictions other than where it was collected. If I am a resident of Quebec, this includes transferring or disclosing my personal information to Medavie Blue Cross employees or service providers outside of that province.

I understand that my consent is only valid for the time it is needed to achieve the purposes outlined herein, unless I withdraw it. I understand I may withdraw my consent at any time. However, in some instances doing so may prevent Medavie Blue Cross from providing me with certain products or services that may be useful to me and/or my dependents. This consent complies with federal and provincial privacy laws.

For more details about our information practices, including how your personal information is protected, how to access or correct personal information, or if you have concerns or questions, please see our Medavie Blue Cross Privacy Statement available at www.medaviebc.ca or call 1-800-667-4511.

Signature of Patient: **Date:** _____ (mm/dd/yyyy)

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3A Patient Support Program (PSP) Enrollment

Is patient enrolled in the Patient Support Program? ☐ No ☐ Yes, specify Program ID #: _____

Indicate the name of the Patient Support Program: _____

PSP phone #: _____ PSP Fax #: _____

Product Name	Strength	Dosage	Diagnosis

Patient weight: _____ ☐ lbs ☐ kg Number of vials / syringes per dose: _____

Date treatment was initiated: _____ (mm/dd/yyyy) Expected duration of treatment: _____

Date of diagnosis: _____ (mm/dd/yyyy) Was treatment initiated in hospital? ☐ Yes ☐ No

Where is medication being administered? _____

Indicate the specialty of the physician who initiated or recommended the treatment: _____

Indicate if the disease or injury is work related: ☐ Yes ☐ No

For Initial Request, please complete sections 3B and 3D. For Renewals, please complete sections 3C and 3D.

3B Initial Request

Please list all the drugs that were previously tried, or could not be tried because of contraindications. The information for the following drug categories (relative to each diagnosis) must be provided, including details on the contraindication if applicable.

- **Rheumatoid arthritis: methotrexate, anti-TNFα (infliximab, adalimumab, etanercept, Simponi, Cimzia), advanced first-line therapies (tofacitinib, Actemra, Kevzara, Rinvoq, Olumiant, Orencia, Kineret)**
- **Granulomatosis with polyangiitis and microscopic polyangiitis: cyclophosphamide, glucocorticoid, rituximab, Tavneos (avacopan)**

Category	Product Name	Dosage	Duration of Treatment	Response to Treatment or Contraindication

Is the drug being prescribed according to the Health Canada product monograph? ☐ Yes ☐ No

*NOTE: Do not provide genetic test results.

Approved indications from Health Canada:

1. **Rheumatoid arthritis**

Administration of treatment:

☐ In combination with methotrexate

☐ In combination with leflunomide. Specify the reason: ☐ Intolerance to methotrexate ☐ Contraindication to methotrexate

☐ In combination with other medications. Specify: _____

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3B Initial Request (cont'd)

1. **Rheumatoid arthritis (cont'd)**

Moderate to severely active disease: ☐ Yes ☐ No

Positive rheumatoid factor: ☐ Yes ☐ No

Number of articulations with active synovitis: _____

Radiologically measured erosions: ☐ Yes ☐ No

Confirm all that apply (prior to treatment):

☐ An elevated sedimentation rate. Specify: _____ mm/h

☐ An elevated C-reactive protein level. Specify: _____ mg/L

☐ Score on the Health Assessment Questionnaire (HAQ): _____

☐ CDAI score: _____

Does the patient have a history of lymphoproliferative disorder (i.e., lymphoma) for which rituximab is an approved treatment? ☐ Yes ☐ No

If the request is for Rituxan, please provide a clinical rationale for avoiding the use of a biosimilar version of rituximab:

_____

_____

2. **Granulomatosis with polyangiitis (GPA) or Wegener's granulomatosis and microscopic polyangiitis (MPA)**

Diagnosis: ☐ Granulomatosis with polyangiitis (GPA) or Wegener's granulomatosis
☐ Microscopic polyangiitis (MPA)

This is a request for: ☐ Induction of remission ☐ Maintenance of remission

Does the patient have severely active disease? ☐ Yes ☐ No

Could the disease lead to organ failure or be life-threatening? ☐ Yes ☐ No

Test for antibodies to proteinase 3-ANCA (PR3): ☐ Positive ☐ Negative ☐ Not performed

Test for antibodies to myeloperoxidase-ANCA (MPO): ☐ Positive ☐ Negative ☐ Not performed

If this is a request for maintenance of remission, was there stabilization of the condition with remission? ☐ Yes ☐ No

↳ Specify the treatment administered (check all that apply):
- ☐ Induction doses of cyclophosphamide and a glucocorticoid as combination
- ☐ Induction doses of rituximab infusion
- ☐ Tavneos (avacopan) was added to induction therapy
- ☐ Other. Specify: _____

If the request is for Rituxan, please provide a clinical rationale for avoiding the use of a biosimilar version of rituximab:

_____

_____

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3B Initial Request (cont'd)

3. **Non-Hodgkin's lymphoma (NHL)**

The drug is prescribed for:

☐ The treatment of a patient with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma.

☐ The treatment of a patient with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

☐ The treatment of a patient with previously untreated stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.

☐ The maintenance treatment of a patient with follicular non-Hodgkin's lymphoma who has responded to induction therapy with either CHOP or CHOP plus rituximab.

☐ Single-agent maintenance treatment of a previously untreated patient with advanced follicular non-Hodgkin's lymphoma with high tumour burden and who has responded to induction therapy with either CHOP plus Rituxan or CVP plus rituximab.

ECOG score (date): _____ (_____)
(mm/dd/yyyy)

Has the patient received and tolerated at least one full dose of rituximab IV? ☐ Yes ☐ No

4. **B-cell chronic lymphocytic leukemia (B-CLL)**

Binet stage: ☐ A ☐ B ☐ C

ECOG score (date): _____ (_____)
(mm/dd/yyyy)

Pharmacological treatment:

☐ First-line treatment ☐ Second-line treatment ☐ Third-line treatment or more

Administration of treatment:

☐ As monotherapy

☐ In combination with fludarabine and cyclophosphamide

☐ In combination with other medications. Specify: _____

Has the patient received and tolerated at least one full dose of rituximab IV? ☐ Yes ☐ No

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3C Renewal Request

Please provide information on the evolution of the disease to evaluate the response to treatment.

Date of initial evaluation (pretreatment): _____ (mm/dd/yyyy)

Date of most recent evaluation: _____ (mm/dd/yyyy)

1. **Rheumatoid arthritis**

Date of last dose of rituximab: _____ (mm/dd/yyyy)

Number of articulations with active synovitis at initial evaluation (pretreatment): _____

Number of articulations with active synovitis at most recent evaluation: _____

ACR score (date): _____ (_____) (mm/dd/yyyy)

Other elements, if initially assessed	Result at initial evaluation	Result at most recent evaluation
C-reactive protein level value (mg/L):		
Sedimentation rate value (mm/h):		
Score on the Health Assessment Questionnaire (HAQ):		
CDAI score:		

Return to work, if applicable (date): ☐ Yes ☐ No (_____) (mm/dd/yyyy)

Response to previous treatment:

☐ The disease is still not in remission

☐ The disease is reactivated following attainment of a remission

☐ Other. Specify: _____

2. **Granulomatosis with polyangiitis (GPA) or Wegener's granulomatosis and microscopic polyangiitis (MPA)**

Request for renewal for a patient that is established on therapy with Rituxan and will continue with Rituxan: ☐ Yes ☐ No

Does the patient have severely active disease? ☐ Yes ☐ No

The patient has (check all that apply):

☐ A history of prior relapse

☐ Significant pre-existing organ damage

☐ PR3-ANCA and/or persistent ANCA positivity

☐ None of the above

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3D Additional Information

Please indicate any additional information pertaining to this request.

MEDAVIE BLUE CROSS™

PRIOR AUTHORIZATION REQUEST

HEALTH PROFESSIONAL STATEMENT

I certify that I have reviewed all pages of this request and that all information provided is true, correct and complete.

First Name: _____ Last Name: _____ Permit Number: _____

Specialty: _____

Clinic Name: _____

Address: _____ Suite: _____

City: _____ Province: _____ Postal Code: _____

E-mail: _____ Telephone: _____ Fax: _____

Signature: Date: _____
(mm/dd/yyyy)

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit.

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480